

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>McDonough John</u> _____ (Last) (First) (Middle) <u>101 HARTWELL AVE</u> _____ (Street) <u>LEXINGTON MA 02421</u> _____ (City) (State) (Zip)			2. Issuer Name and Ticker or Trading Symbol <u>T2 Biosystems, Inc. [ TTOO ]</u>		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner _____ Officer (give title below) Other (specify below)	
			3. Date of Earliest Transaction (Month/Day/Year) <u>01/08/2020</u>			
			4. If Amendment, Date of Original Filed (Month/Day/Year)		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person _____ Form filed by More than One Reporting Person	

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/08/2020		M		16,666	A	(1)	470,285 <sup>(2)</sup>	D	
Common Stock	01/08/2020		M		100,000	A	(1)	570,285	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Performance Restricted Stock Units	(1)	01/08/2020		D			326,087	(3)	(3)	Common Stock	326,087	\$0.00	0	D	
Restricted Stock Units	(1)	01/08/2020		M			16,666	(4)	(4)	Common Stock	16,666	\$0.00	0	D	
Restricted Stock Units	(1)	01/08/2020		M			100,000	(4)	(4)	Common Stock	100,000	\$0.00	0	D	

**Explanation of Responses:**

- Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- Includes 5,399 shares acquired under the Issuer's employee stock purchase plan on May 15, 2019.
- On March 15, 2018, the reporting person was granted Performance Restricted Stock Units that vest in the form of common stock based upon the achievement of certain pre-established 90-day average daily closing prices per share goals over a three year performance period. On January 8, 2020, the reporting person incurred a termination of service and forfeited the remaining unvested RSU's subject to this grant.
- Pursuant to the terms of that certain Employment Agreement by and between the reporting person and Issuer, dated March 4, 2008, as amended by that certain First Amendment to Employment Agreement, dated July 7, 2014 and that certain Second Amendment to Employment Agreement, dated July 30, 2019, upon the reporting person's resignation as Chief Executive Officer, these RSUs automatically vested on January 8, 2020.

**Remarks:**

/s/ John Sprague, Attorney-in-fact 01/10/2020

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.